Pereira Daniel E, Ford Caleb, Mittal Mehul M, Lee Tiffany M, Joseph Karan, Madrigal Sabrina C, Momtaz David, Torres-Izquierdo Beltran, Hosseinzadeh Pooya
Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri.
Department of Orthopaedics, UT Southwestern Medical Center, Dallas, Texas.
J Bone Joint Surg Am. 2025 Jan 1;107(1):66-72. doi: 10.2106/JBJS.23.01225. Epub 2024 Nov 12.
Nonunion is a rare yet serious complication in pediatric fracture healing that can lead to patient morbidity and economic burden. The administration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been associated with an increased risk of fracture nonunion in adults, but data are lacking in the pediatric population. This study examines the relationship between postoperative ketorolac administration and nonunion in operatively managed pediatric long-bone fractures.
A retrospective cohort study was conducted with use of TriNetX, a research network that encompasses data from the United States, Canada, and Western Europe. A total of 462,260 patients from 52 health-care organizations met the inclusion criteria. Patients <18 years old with operatively managed upper or lower-extremity long-bone fractures were included. The exposure of interest was ketorolac administration within 30 days postoperatively between 2003 and 2023. Nonunion was identified and verified with use of the pertinent medical codes. Absolute risks and hazard ratios (HRs) were calculated for both study groups. Significance was set at p < 0.05.
After propensity score matching, 48,778 patients were identified per group. The incidence of nonunion was 2.19% in the ketorolac group and 0.93% in the non-ketorolac group (HR, 2.71; 95% confidence interval [CI]: 2.46, 3.21; p < 0.0001). Subgroup analyses demonstrated a higher risk of nonunion in patients with lower-extremity fractures (HR, 3.45; 95% CI: 3.14, 3.75; p < 0.0001) than in those with upper-extremity fractures (HR, 2.11; 95% CI: 1.84, 2.32; p < 0.0001). Among the fracture location subgroups, the greatest HR for nonunion was observed in patients with femoral fractures, followed sequentially by those with tibial and/or fibular fractures, humeral fractures, and radial and/or ulnar fractures.
To our knowledge, this is the largest study to date to explore postoperative ketorolac use and nonunion in the setting of operatively managed pediatric long-bone fractures. Nonunion in children was rare, occurring in <1% of all included patients. Ketorolac administration was associated with a 2 to 3-fold increase in nonunion risks, with pronounced implications for patients with lower-extremity fractures, particularly those with femoral fractures. Clinicians should weigh the therapeutic advantages of non-opiate analgesia with ketorolac against the risk of nonunion in order to optimize postoperative pain management and recovery.
Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
骨折不愈合是小儿骨折愈合过程中一种罕见但严重的并发症,可导致患者发病并带来经济负担。在成人中,使用非甾体类抗炎药(NSAIDs)与骨折不愈合风险增加有关,但小儿群体的数据尚缺乏。本研究探讨了小儿长骨骨折手术治疗后使用酮咯酸与骨折不愈合之间的关系。
利用TriNetX进行了一项回顾性队列研究,TriNetX是一个涵盖美国、加拿大和西欧数据的研究网络。来自52个医疗机构的462260名患者符合纳入标准。纳入年龄小于18岁、接受手术治疗的上肢或下肢长骨骨折患者。感兴趣的暴露因素是2003年至2023年间术后30天内使用酮咯酸。通过相关医疗编码识别并验证骨折不愈合情况。计算两个研究组的绝对风险和风险比(HRs)。显著性设定为p<0.05。
倾向评分匹配后,每组确定了48778名患者。酮咯酸组骨折不愈合发生率为2.19%,非酮咯酸组为0.93%(HR,2.71;95%置信区间[CI]:2.46,3.21;p<0.0001)。亚组分析表明,下肢骨折患者骨折不愈合风险(HR,3.45;95%CI:3.14,3.75;p<0.0001)高于上肢骨折患者(HR,2.11;95%CI:1.84,2.32;p<0.0001)。在骨折部位亚组中,股骨骨折患者骨折不愈合的HR最高,其次依次为胫腓骨骨折、肱骨骨折以及桡尺骨骨折患者。
据我们所知,这是迄今为止探索小儿长骨骨折手术治疗后使用酮咯酸与骨折不愈合关系的最大规模研究。小儿骨折不愈合罕见,在所有纳入患者中发生率不到1%。使用酮咯酸会使骨折不愈合风险增加2至3倍,对下肢骨折患者影响尤其明显,特别是股骨骨折患者。临床医生应权衡酮咯酸非阿片类镇痛的治疗优势与骨折不愈合风险,以优化术后疼痛管理和康复。
治疗性III级。有关证据水平的完整描述,请参阅作者指南。